| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Institut National de la Santé et de la Recherche Médicale U460,* Cardiovascular Remodeling, Hôpital Xavier Bichat, Paris, France; Institut National de la Santé et de la Recherche Médicale U36, Collège de France, Paris, France; and the Department of Vascular Surgery, Hôpital Charles Nicolles, Rouen, France
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
2-anti-plasmin complexes were detected demonstrating in vivo the activation of plasminogen. In contrast, u-PA and t-PA were detectable only in the wall, suggesting that plasminogen present in the thrombus could be activated by factors secreted by the arterial wall. This was demonstrated in vitro, in which co-incubation of thrombus and wall extracts generated plasmin in the presence of a fibrin matrix and activated MMPs. In conclusion, our study strongly suggests that the mural thrombus, by trapping polymorphonuclear leukocytes and adsorbing plasma components could act as a source of proteases in aneurysms that may play a critical role in enlargement and rupture.
The development of acquired abdominal aortic aneurysms of atheromatous origin is usually characterized by the presence of a mural thrombus. Despite this observation, previous studies have mainly focused on the localization of proteinases within the aneurysmal wall,5-8
and only a few have explored the involvement of the thrombus in aneurysmal evolution.9
In contrast with arterial occlusive diseases, blood flow is maintained through the aneurysmal thrombus resulting in a persistent remodeling activity of its components.10
Evolution of aneurysmal diameter has been reported to correlate with plasma markers of fibrin formation and degradation,11
and circulating plasmin (Pn)-2-anti-Pn12
corresponding to thrombus turnover. Furthermore, the presence of a crescent sign on computed tomography scan, corresponding to a hemorrhage within the thrombus, is considered as a predictive marker of imminent rupture.13
The purpose of this study was to determine the differential localization of proteinases and their activators within the thrombus and the aneurysmal wall and their release into the liquid phase that is present at the interface between thrombus and wall. First, we explored the ability of blood clots to store and release matrix metalloproteinases (MMPs) during their formation and lysis in vitro. MMPs and the Pg activation cascade were then investigated in aneurysmal thrombus, wall, and their liquid interface. Our data strongly suggest that the thrombus represents a site of storage and release of leukocyte and plasma proteinases, and its parietal surface, a target for activators present in the wall.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Sera were obtained after incubation of blood at 37°C for 30 minutes; 9, 32, and 56 hours; and 3, 4, and 7 days. Citrated plasma samples were used directly or recalcified (30 mmol/L CaCl2) to induce fibrin formation in the absence of blood cells. To analyze the cellular source of proteases, polymorphonuclear leukocytes (PMNs), monocytes, lymphocytes, and platelets were isolated as previously described (n = 5, 5 ml per volunteer).14,15 MMPs were extracted in 0.05 mol/L of Tris-HCl, pH 7.5, containing 0.01 mol/L of CaCl2 and 0.2% Triton X-100. Homogenates were sonicated and centrifuged and supernatants were collected. Protein concentration was determined by the Bradford assay (Bio-Rad, Ivry-sur-Seine, France).
Tissue Samples
Infrarenal aortic specimens were obtained from 35 patients who provided informed consent before surgical abdominal aortic aneurysm repair. The largest diameter of the aneurysm was measured on computed tomography scan (mean diameter, 57.9 ± 17.7 mm; range, 36 to 120 mm). Thrombi (n = 35) and aneurysmal walls (n = 35) were harvested separately during surgery and quickly frozen in liquid nitrogen. In 15 patients, a liquid phase was present at the interface between thrombus and wall, which we assume to be a consequence of the fibrinolysis at the abluminal pole of the thrombus, and was sampled separately.
Protein Extraction
Tissue samples were homogenized in 0.05 mol/L of Tris-HCl, pH 7.5, containing 0.01 mol/L of CaCl2, 2 mol/L of guanidinium chloride, and 0.2% Triton X-100 using a Polytron as previously described.16 Protein concentration was determined by the Bradford assay (Bio-Rad).
Gelatin and -Casein Zymographies
Extracts (10 or 30 µg of proteins) were analyzed by electrophoresis on 10% sodium dodecyl sulfate-polyacrylamide gels containing 1 mg/ml of gelatin (Sigma, St. Quentin-Fallavier, France) or -casein (Fluka-St. Quentin-Fallavier, France) under nonreducing conditions as previously described.16
Activities were quantified by densitometry using the NIH Image 1.60 ppc software. A standard sample was run on each gel and served as reference.
Reverse Gelatin Zymography
Extracts (50 µg of proteins) were submitted to 13% sodium dodecyl sulfate-polyacrylamide gel electrophoresis on gels that contained 1 mg/ml of gelatin and 160 ng/ml of pro-MMP-2 (Euromedex, Souffelweyersheim, France) under nonreducing conditions as previously described.17 A solution of TIMP-1 and -2 (Euromedex) was used as reference.
Immunohistochemistry for MMP-9, Platelets, and PMN Staining
Seven-µm cryostat sections obtained of aneurysmal thrombi were mounted on poly-L-lysine-coated slides and fixed in acetone. Some sections were then treated with 3% H2O2 for 10 minutes at room temperature and incubated overnight at 4°C with anti-MMP-9 monoclonal (Ab-1; Calbiochem, Meudon, France), and anti-GPIIb/IIIa monoclonal (7E3; Dr. JP Rosa, INSERM U348, Paris)18
primary antibodies (10 µg/ml). Sections were then processed using biotin-streptavidin-peroxidase complexes. Peroxidase activity was revealed with diaminobenzidine/cobalt substrate. Negative controls included omission of the primary antibody or replacement of the primary antibody with naïve mouse IgG1
(10 µg/ml). Other serial sections were stained with hematoxylin, phloxin, and safran to evaluate general topography and cell distribution.
Pg and Pn Activities
Pg quantity in each extract was determined on tPA-fibrin-coated wells.19 For tPA (Biopool, American Diagnostica, Andresy, France) coating, 50 µl of t-PA [20 IU/ml in phosphate-buffered saline buffer and 2 mg/ml of bovine serum albumin (BSA)] were incubated in fibrin-coated wells for 1 hour at 37°C. After washing, 25 µl of each sample and 25 µl of 1.5 mmol/L CBS 0065 (Diagnostica Stago, Asnières, France) were added and incubated at 37°C. The Pg activation is detected by measuring the change in absorbance at 405 nm as a function of time (0 to 2 hours) using a microplate reader (Dynex, Issy-les-Moulineaux, France). Results were expressed as nmol of Pg/mg soluble proteins by reference to a standard curve constructed with purified Pg. Plasmin (Pn) activity was determined in the same samples on 4% BSA-coated wells. Initial rates of p-nitro-aniline release from the chromogenic substrate were transformed into pmol of Pn/mg soluble proteins as previously described.19
Pg Activator Zymography
Fifty µg of proteins were electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis as previously described.20 The gel was then carefully overlaid on a Pg-fibrin-agar gel, incubated at 37°C for 24 to 96 hours in a moist chamber and photographed at regular intervals using dark-ground illumination. Fibrinolytic activities were quantified by densitometry using the NIH Image 1.60 ppc software. Purified t-PA (Biopool) and u-PA (Choay, Gentilly, France) were used as reference.
Analysis of Pg and MMP Activation by Thrombus/Wall Interactions in Vitro
Extracts of thrombus and wall (100 µl) were first depleted in Pn by adsorption on aprotinin-Sepharose. Thirty µl of Pn-free wall extract was then preincubated with or without a fibrin matrix for 2 hours at 37°C. After washing with phosphate-BSA buffer, 20 µl of Pn-free thrombus extract and chromogenic substrate selective for Pn (CBS 0065) were added. The activation of Pg present in the extract was monitored in a microplate reader. In parallel experiments, wall and thrombus extracts were co-incubated with or without a fibrin matrix for 24 hours at 37°C and further analyzed by gelatin zymography to visualize MMP activation.
Western Blot
Electrophoresis was performed as described by Laemmli on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels under reducing conditions.16
Antibodies to kringle 1 of Pn/Pg as previously described,21
2-anti-Pn (Biopool); MMP-2, -3, -7, and -9; and TIMP-1 and -2 (Chemicon, Euromedex, Souffelweyersheim, France), were used at the concentration of 1 µg/ml and horseradish peroxidase IgG (DAKO, Trappes, France) was used after dilution (1/1000). Peroxidase activity was detected using chemiluminescence reagent (NEN, Courtaboeuf, France).
Statistical Analysis
Data are expressed as means ± SD. The paired t-test and one-way factorial analysis (analysis of variance) followed by the Scheffé F-test were used to compare groups. Differences were considered significant when P < 0.05.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
To demonstrate that the thrombus can indeed be a source of storage and release of MMPs, gelatinase activities were measured in plasma versus serum and in blood cell pellet versus blood clot sampled from healthy volunteers.
Pro-MMP-9 and pro-MMP-2 activities were similar in plasma and in serum-derived plasma, ie, respectively, before and after addition of 30 mmol/L CaCl2, respectively, which results in fibrin formation (Figure 1A)
. Thus, there was no adsorption of pro-MMP-9 and pro-MMP-2 activities during fibrinogenesis in the absence of blood cells, including platelets.
|
. Pro-MMP-9 further increased in serum during clot retraction and lysis (P < 0.01) (Figure 1A)
. Conversely, pro-MMP-9 content was lower in the clot than in the blood cell pellet (P < 0.01) (Figure 1B)
. Pro-MMP-9 activity further decreased in the clot during thrombus lysis (P < 0.01). Pro-MMP-9 was thus released during clot formation, retraction, and lysis in vitro.
Pro-MMP-2 activity in serum was slightly higher than in plasma (P < 0.01, Figure 1A
). Pro-MMP-2 activity was not modified during clot retraction and decreased during clot lysis (P < 0.01). In cell pellet and blood clots, pro-MMP-2 activities were very low (Figure 1B)
.
To analyze the cellular source of MMPs during clot formation, PMNs, monocytes/lymphocytes, and platelets were isolated and MMPs were extracted from cell pellets. Pro-MMP-9 activity was significantly higher in PMNs than in platelets (P < 0.001) and significantly lower in platelets than in monocytes/lymphocytes (P < 0.01). Low pro-MMP-2 activity was found only in platelet extracts (Figure 2A)
.
|
There was no significant difference between the soluble protein contents of mural thrombus and aneurysmal wall (23 ± 6 and 20 ± 7 mg/ml, respectively) but a significantly higher concentration was detected in the liquid interface (124 ± 14 mg/ml).
Gelatinolytic activities detected at apparent molecular weight of 96 kd correspond to pro-MMP-9 (Figure 3A)
. This identity was confirmed by Western blot (Figure 3B)
. The proform of MMP-9 was detected in thrombus, liquid, and wall whereas the active form was only detected in the liquid interface between thrombus and wall (Figure 3A)
.
|
. This identity was again confirmed on Western blot (Figure 3B)
. Latent and active MMP-2 were similarly detected in thrombus, wall, and liquid (Figure 3D)
.
Mean MMP-9 and MMP-2 activities were similar in the three compartments (Figure 3, C and D)
; however, the MMP-9/MMP-2 ratio was 2.5-fold higher in the thrombus than in the wall and liquid interface (P < 0.01) (Figure 3E)
.
MMP-9 and PMN Leukocytes Are Present in the Thrombus
Hematoxylin, phloxin, and safran staining of sections showed a marked enrichment of polymorphonuclear cells in the most inner layer of the mural thrombus. In contrast the abluminal thrombus is devoid of cellular components (Figure 4A)
. PMN smears were used as a positive control for MMP-9 immunostaining (data not shown). MMP-9 immunostaining co-localized exactly with PMNs. There was no MMP-9 immunostaining in the abluminal part of the thrombus (Figure 4B)
. Platelet smears were used as a positive control for GPIIb/IIIa immunostaining and were strictly negative for MMP-9 (data not shown). The GPIIb/IIIa immunostaining showed an intense staining in the luminal thrombus (Figure 4C)
.
|
Casein zymography showed lytic activities at 50 kd and 28 kd (data not shown). By Western blotting, these activities were characterized as MMP-3 and MMP-7, respectively. MMP-3 and MMP-7 activities and proteins were detected only in the aneurysmal wall (data not shown).
TIMP-1 and -2 Are Significantly Lower in the Liquid Interface
MMP-2 inhibitory activities were detectable at apparent molecular weights of 27 kd and 21 kd in tissue extracts and were shown to correspond to TIMP-1 and -2 on Western blot (data not shown). TIMP-1 activity was similar in thrombus and wall (55,930 ± 28,860 and 57,607 ± 30,141 D.U./mg soluble proteins, respectively) and significantly lower in the liquid interface (25,890 ± 19,810 D.U./mg soluble proteins, P < 0.001). TIMP-2 activity was significantly higher in the wall than in the thrombus (67,810 ± 32,250 and 46,130 ± 25,790 D.U./mg soluble proteins, respectively, P < 0.01) and in the liquid interface (31,180 ± 14,500 D.U./mg soluble proteins, P < 0.01).
Pg Is Localized in the Mural Thrombus
Pn, as a possible activator of MMPs, and its precursor Pg were detected by Western blotting, and their activities were measured on a synthetic substrate. Pg was significantly higher in the mural thrombus than in the liquid interface and was not detected in the wall (Figure 5, A and C)
(P < 0.01). Pn activity was similar in thrombus and wall extracts and was not detected in the liquid interface (Figure 5, A and D)
. The absence of Pn activity in the liquid interface may be because of the presence of inhibitors. Indeed, 2-anti-Pn and Pn-2-anti-Pn complexes were detected in the liquid interface as shown on Western blot (Figure 5B)
. Pn-2-anti-Pn complexes were also detected in extracts of thrombus and wall (data not shown).
|
Fibrin-Pg zymography showed activities at apparent molecular weights of 120, 70, and 54 kd (Figure 6A)
. Enzyme activity at 70 kd was inhibited by polyclonal antibodies to t-PA and activities at 120 and 54 kd were inhibited by polyclonal antibodies to u-PA (data not shown). The enzyme activities at 120 and 54 kd correspond to u-PA-PAI-1 complexes and free u-PA, respectively; the enzyme activity at 70 kd corresponds to free t-PA. The u-PA-PAI-1 complexes were detected in thrombus, liquid interface, and wall (Figure 6, A and D)
. Free t-PA and u-PA activities were only measurable in the arterial wall (Figure 6;A, B, and C)
. t-PA-PAI-1 complexes were not detected.
|
To explain the role of the interaction of the thrombus with wall components, extracts of thrombus and wall were co-incubated in absence or presence of a fibrin matrix in vitro. When the two extracts were co-incubated for 2 hours at 37°C in BSA-coated wells, there was no generation of Pn. In contrast, in fibrin-coated wells, incubation of thrombus extracts, which contain Pg (Figure 5C)
, with wall extracts, which contain activators (Figure 6, B and C)
, induced formation of Pn (Figure 7A)
.
|
. These data suggest an interaction between the substrates present in the thrombus and the activators secreted by the wall and a catalyzing role of the solid-phase fibrin in the generation of Pn at the interface between thrombus and wall. |
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Ex vivo analysis of the mural thrombus gave parallel results showing a higher MMP-9/MMP-2 ratio compared to the wall. Histology demonstrated the accumulation of PMNs in the inner layer of the thrombus and their co-localization with MMP-9 staining. By analogy to our in vitro observations, these data suggest that MMP-9 could be stored and released by PMNs entrapped in the thrombus on its luminal side. Adolph and co-workers10 have shown that the aneurysmal thrombus is active. This activity is associated with a leukocyte gradient from the luminal to the abluminal pole of the thrombus.10 Monocyte/macrophages25 and PMNs26 easily adhere to the co-polymer of fibrin-fibronectin, and PMNs release latent MMP-9 when they adhere to fibronectin-collagen co-polymer.27 Similarly, Sakalihasan and co-workers9 reported an enrichment of MMP-9 in aneurysms that was associated with a negative gradient of latent MMP-9, and a positive one for MMP-9 activation, from the luminal to the parietal pole of the thrombus. Our ex vivo evidence of PMN trapping and MMP-9 storage within the aneurysmal thrombus associated with the in vitro demonstration of the role of leukocyte trapping in MMP-9 storage and release during thrombus formation strongly suggest that the active luminal pole of the thrombus could trap circulating leukocytes that then release pro-MMP-9. Pro-MMP-9 could be both stored within the aneurysmal thrombus and released into the circulating blood. Therefore MMP-9 release by the luminal thrombus could be also the main source of high levels of plasma MMP-9 reported in patients with aortic aneurysms.28 The reported normalization of plasma pro-MMP-9 levels by aneurysm repair may predominantly reflect exclusion of the thrombus;29 and conversely, the absence of regression of these levels would suggest the persistence of a thrombus activity, providing evidence of endoleaks.30
Nevertheless, pro-MMP-9 was also present in the aneurysmal wall,31 probably mainly synthesized by infiltrated inflammatory cells or diffusing from the thrombus.32 The important role of MMP-9 in aneurysm development and evolution has been recently stressed by experimental approaches showing that MMP-9 gene disruption in mice prevented the development of elastase-induced aneurysms33 and that smooth muscle endoluminal seeding prevented both experimental aneurysm development and MMP-9 expression.17
In contrast with pro-MMP-9, pro-MMP-2 activity in vitro was only slightly higher in serum than in plasma, corresponding to a small release during clot formation. This release of pro-MMP-2 probably provides evidence of platelet aggregation associated with thrombus formation.34 Latent MMP-2 is constitutively expressed and secreted by vascular cells.35,36 and diffuses easily into the culture medium when tissue is incubated ex vivo.35
MMP-3 and -7, revealed by their caseinolytic activity, are only present in the arterial wall. MMP-3 (stromelysin 1) is expressed in human aneurysmal wall37 and mainly secreted by inflammatory cells.38 MMP-3 is also involved in the activation of MMP-9.39 Because MMP-3 possesses a hemopexin-like domain40 it binds to heparan sulfate41-43 and could be stored in tissue.
MMP-7 (matrilysin) is also a MMP tightly bound to heparan sulfate.41 Pro-MMP-7 is mainly synthesized and secreted by activated fibroblasts.44 In response to proteolytic medial injury, adventitial fibroblasts activate, proliferate, and secrete collagen limiting the outward expansion of aneurysm.45 The presence of MMP-7 in the aneurysmal wall probably provides evidence of the activity of adventitial fibroblasts in aneurysmal remodeling.
We explored also the localization of Pg activation able to form active MMPs. Pg was present in the thrombus and liquid interface, and absent in the wall. Circulating Pg binds to fibrin and is adsorbed from the plasma onto the aneurysmal thrombus, serving as a substrate for Pn generation. Pn is detectable in both thrombus and wall but, in the thrombus, the quantity of Pn is 3000-fold lower than that of Pg. In contrast, free Pg activators were only detectable in the wall. u-PA is mainly produced by inflammatory cells in the wall and its role in aneurysm development has been recently pointed out through experimental approaches.46,47
For the first time we observe here the complementary localization of the substrate Pg in the thrombus and its activators in the aneurysmal wall suggesting a cooperation between thrombus and wall in generating active Pn which probably plays a major role in MMP activation on the parietal surface of the thrombus. To demonstrate these points, thrombus and wall extracts were co-incubated in vitro and our results showed the ability of this interaction to activate MMPs and the fibrin-dependency of Pn generation. The presence of a fibrinolytic liquid phase containing active MMPs at the interface between aneurysmal thrombus and wall also provides evidence of such activation in vivo. The absence of detectable free Pn in this liquid interface and the presence of Pn-2-anti-Pn complexes, contrasting with the finding of active Pn in the thrombus and the wall, also suggest that a solid phase is critical for Pn activity, thrombus lysis, and MMP activation. These data fit well with the reported predominant localization on in situ zymography of MMP activities in the inner wall of human aneurysms.48
In conclusion, our study strongly suggests that the mural thrombus, by aggregating platelets, trapping circulating cells, and adsorbing plasma components, could act as a source of secreted proteases within the aneurysm. In contrast, the arterial wall contains mainly tissue proteases, including MMPs and Pg activators of inflammatory and mesenchymal cell origin. Finally, the abluminal part of the thrombus could serve as a solid phase catalyst between the thrombus and the wall. The formation of a liquid fibrinolytic phase at the interface between thrombus and wall, devoid of Pn activity but containing active forms of MMPs, provides evidence of these topological interactions between substrates vehiculed by the thrombus and activators originating from the wall. These proteases linked to thrombus activities could play a critical role in the evolution of abdominal aortic aneurysms toward enlargement and rupture.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by a Progres grant from INSERM, the Fondation de France, and by a grant from the Société de Chirurgie Vasculaire (to V. F.).
Accepted for publication July 24, 2002.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  J. S. Lindholt, H. T. Sorensen, J. B. Michel, H. F. Thomsen, and E. W. Henneberg Low-Dose Aspirin May Prevent Growth and Later Surgical Repair of Medium-Sized Abdominal Aortic Aneurysms Vascular and Endovascular Surgery, August 1, 2008; 42(4): 329 - 334. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Hlawaty, A. San Juan, M.-P. Jacob, R. Vranckx, D. Letourneur, and L. J. Feldman Inhibition of MMP-2 gene expression with small interfering RNA in rabbit vascular smooth muscle cells Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3593 - H3601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mannello, G.A.M. Tonti, and F. Canestrari The `never-ending story' of the influence of blood specimen collection methods affecting the concentration, the zymographic profile and the usefulness of matrix metalloproteinases and their tissue inhibitors in multiple sclerosis diagnosis/prognosis: a landmark for limiting the misuse of serum samples Multiple Sclerosis, June 1, 2007; 13(5): 687 - 690. [PDF]
|
|
|
|
 |
|
 R. Kadirvel, D. Dai, Y.H. Ding, M.A. Danielson, D.A. Lewis, H.J. Cloft, and D.F. Kallmes Endovascular Treatment of Aneurysms: Healing Mechanisms in a Swine Model Are Associated with Increased Expression of Matrix Metalloproteinases, Vascular Cell Adhesion Molecule-1, and Vascular Endothelial Growth Factor, and Decreased Expression of Tissue Inhibitors of Matrix Metalloproteinases AJNR Am. J. Neuroradiol., May 1, 2007; 28(5): 849 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Mitchell and P. Libby Vascular Remodeling in Transplant Vasculopathy Circ. Res., April 13, 2007; 100(7): 967 - 978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ikonomidis, J. A. Jones, J. R. Barbour, R. E. Stroud, L. L. Clark, B. S. Kaplan, A. Zeeshan, J. E. Bavaria, J. H. Gorman III, F. G. Spinale, et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves J. Thorac. Cardiovasc. Surg., April 1, 2007; 133(4): 1028 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Houard, A. Leclercq, V. Fontaine, M. Coutard, J.-L. Martin-Ventura, B. Ho-Tin-Noe, Z. Touat, O. Meilhac, and J.-B. Michel Retention and Activation of Blood-Borne Proteases in the Arterial Wall: Implications for Atherothrombosis J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A3 - A9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Blanco-Colio, J. L. Martin-Ventura, F. Vivanco, J.-B. Michel, O. Meilhac, and J. Egido Biology of atherosclerotic plaques: What we are learning from proteomic analysis Cardiovasc Res, October 1, 2006; 72(1): 18 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sarda-Mantel, M. Coutard, F. Rouzet, O. Raguin, J.-M. Vrigneaud, F. Hervatin, G. Martet, Z. Touat, P. Merlet, D. Le Guludec, et al. 99mTc-Annexin-V Functional Imaging of Luminal Thrombus Activity in Abdominal Aortic Aneurysms Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2153 - 2159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shimizu, R. N. Mitchell, and P. Libby Inflammation and Cellular Immune Responses in Abdominal Aortic Aneurysms Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 987 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Touat, V. Ollivier, J. Dai, M.-G. Huisse, A. Bezeaud, U. Sebbag, T. Palombi, P. Rossignol, O. Meilhac, M.-C. Guillin, et al. Renewal of Mural Thrombus Releases Plasma Markers and Is Involved in Aortic Abdominal Aneurysm Evolution Am. J. Pathol., March 1, 2006; 168(3): 1022 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Johnson, S. J. George, A. C. Newby, and C. L. Jackson Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries PNAS, October 25, 2005; 102(43): 15575 - 15580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Upchurch Jr Gene Therapy to Treat Aortic Aneurysms: Right Goal, Wrong Strategy Circulation, August 16, 2005; 112(7): 939 - 940. [Full Text] [PDF]
|
|
|
|
|
|
J. Dai, F. Losy, A.-M. Guinault, C. Pages, I. Anegon, P. Desgranges, J.-P. Becquemin, and E. Allaire Overexpression of Transforming Growth Factor-{beta}1 Stabilizes Already-Formed Aortic Aneurysms: A First Approach to Induction of Functional Healing by Endovascular Gene Therapy Circulation, August 16, 2005; 112(7): 1008 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Eliason, K. K. Hannawa, G. Ailawadi, I. Sinha, J. W. Ford, M. P. Deogracias, K. J. Roelofs, D. T. Woodrum, T. L. Ennis, P. K. Henke, et al. Neutrophil Depletion Inhibits Experimental Abdominal Aortic Aneurysm Formation Circulation, July 12, 2005; 112(2): 232 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Hannawa, J. L. Eliason, D. T. Woodrum, C. G. Pearce, K. J. Roelofs, V. Grigoryants, M. J. Eagleton, P. K. Henke, T. W. Wakefield, D. D. Myers, et al. L-Selectin-Mediated Neutrophil Recruitment in Experimental Rodent Aneurysm Formation Circulation, July 12, 2005; 112(2): 241 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Fondard, D. Detaint, B. Iung, C. Choqueux, H. Adle-Biassette, M. Jarraya, U. Hvass, J.-P. Couetil, D. Henin, J.-B. Michel, et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors Eur. Heart J., July 1, 2005; 26(13): 1333 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kazi, C. Zhu, J. Roy, G. Paulsson-Berne, A. Hamsten, J. Swedenborg, U. Hedin, and P. Eriksson Difference in Matrix-Degrading Protease Expression and Activity Between Thrombus-Free and Thrombus-Covered Wall of Abdominal Aortic Aneurysm Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1341 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Debret, F. Antonicelli, A. Theill, W. Hornebeck, P. Bernard, M. Guenounou, and R. Le Naour Elastin-Derived Peptides Induce a T-Helper Type 1 Polarization of Human Blood Lymphocytes Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1353 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Behmoaras, M. Osborne-Pellegrin, D. Gauguier, and M.-P. Jacob Characteristics of the aortic elastic network and related phenotypes in seven inbred rat strains Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H769 - H777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sibon, D. Larrieu, K. el Hadri, N. M |
, 
, 
: three representative experiments, initial rates: 364, 306, 226 fmol/min, respectively, and •: control experiments in BSA-coated wells). Co-incubated extracts were analyzed on gelatin zymography (B). Percentage of active MMP-9 (C) and MMP-2 (D) were calculated in the presence or absence of fibrin matrix. **, P < 0.01; ***, P < 0.001.